You just read:

MYR Pharma Announces Presentation of Interim Results of MYR 203, a Phase 2 Study of Myrcludex in Combination with Pegylated Interferon in Chronic Hepatitis Delta

News provided by

MYR Pharma

Oct 29, 2018, 04:50 ET